Key facts
- Heligenics’s last known valuation is $17.2M (Aug 2022).
- It has raised $6.0M across 3 recorded rounds; the latest was Seed Round ($2.6M) in Aug 2024.
- Notable investors include Battle Born Venture, City of Las Vegas, Las Vegas Foundation, Nevada Governor's Office of Economic Development, University of Nevada.
- Heligenics has filed 3 Form Ds with the SEC since 2020, most recently Jan 2025 ($2.6M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Heligenics
Funding rounds
3 roundsAbout Heligenics
Developer of a medicinal drug designed to prevent disease and heal patients afflicted with illness through genomics. The company offers a genetic testing and drug discovery by determining the function of genetic variation and can comprehensively measure the functional significance of naturally occurring mutations in the human genome, enhancing the accuracy of genetic testing whether for rare diseases or cancer, enabling the medical industry to get an improve genetic test interpretation and the pharmaceutical companies to empower conversion of generic drugs into targeted precision medicines.
- Sector
- Healthcare
- HQ
- Las Vegas, NV, United States
- Founded
- 2015
- Employees
- 7
- Website
- heligenics.com/
- Ownership
- Privately Held (backing)
Heligenics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Heligenics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Heligenics in its N-PORT filings yet. We sweep new filings monthly.